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ABSTRACT
Presence of excess unaltered, wild-type (WT) DNA
providing no information of biological or clinical
value often masks rare alterations containing diag-
nostic or therapeutic clues in cancer, prenatal di-
agnosis, infectious diseases or organ transplanta-
tion. With the surge of high-throughput technolo-
gies there is a growing demand for removing unal-
tered DNA over large pools-of-sequences. Here we
present nuclease-assisted minor-allele enrichment
with probe-overlap (NaME-PrO), a single-step ap-
proach with broad genome coverage that can re-
move WT-DNA from numerous sequences simultane-
ously, prior to genomic analysis. NaME-PrO employs
a double-strand-DNA-specific nuclease and overlap-
ping oligonucleotide-probes interrogating WT-DNA
targets and guiding nuclease digestion to these
sites. Mutation-containing DNA creates probe-DNA
mismatches that inhibit digestion, thus subsequent
DNA-amplification magnifies DNA-alterations at all
selected targets. We demonstrate several-hundred-
fold mutation enrichment in diverse human samples
on multiple clinically relevant targets including tu-
mor samples and circulating DNA in 50-plex reac-
tions. Enrichment enables routine mutation detec-
tion at 0.01% abundance while by adjusting condi-
tions it is possible to sequence mutations down to
0.00003% abundance, or to scan tumor-suppressor
genes for rare mutations. NaME-PrO introduces a
simple and highly parallel process to remove un-
informative DNA sequences and unmask clinically
and biologically useful alterations.
INTRODUCTION
Traces of alteredDNA in clinical samples provide vital clues
regarding disease states and preferred treatments. Detect-
ing such information-rich, altered DNA sequences, which
often exist within a large excess of normal wild-type (WT)
DNA, pose a persistent technical challenge in several fields
of biology, biotechnology and medicine. These include can-
cer, prenatal diagnosis, infectious diseases, organ transplan-
tation and forensics (1–5). Removing the vast majority of
normal DNA that does not provide meaningful scientific
or clinical information would be a major boon to reveal-
ing and capturing the wealth of information that altered
DNA offers. For example in liquid biopsy of cancer us-
ing circulating-freeDNA (cfDNA) (6–10), traces of somatic
mutations serve as biomarkers for early detection (10) or
tumor response to treatment (11,12), yet the high excess of
circulating WT DNA often dims the opportunities for di-
agnosis and treatment. While several methods for reducing
WT DNA before, during or after polymerase chain reac-
tion (PCR) amplification have been reported (13–18), these
usually apply to single or limited numbers of PCR ampli-
cons or are only applicable to a minority of DNA targets
recognized by sequence-specific enzymes (19–23). Addition-
ally, PCR amplification itself may contribute to false posi-
tive calls in view of polymerase mis-incorporations that are
indistinguishable from DNA alterations (24). With the re-
cent surge of high-throughput technologies (25–27) there
has been an even greater demand for removing unaltered
DNA over large pools of sequences, e.g. prior to perform-
ing massively parallel sequencing (MPS). Under standard
operating conditionsMPS cannot discriminate reliably mu-
tations lower than about 2% abundance (24,28). While the
accuracy of sequencing calls can be improved with molec-
ular barcoding and multiple sequence readout (24,29–33)
these approaches uniformly require an excessive number of
reads for each target, the vast majority of which are non-
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informative, thus wasting time and reagents while also lim-
iting throughput.
Here we present a new technology, Nuclease-Assisted
Minor-Allele enrichment using Overlapping Probes
(NaME-PrO) for removing excess unaltered DNA from
an almost unlimited number of DNA targets simultane-
ously, thereby uniformly improving detection limits for all
endpoint detection technologies. NaME-PrO is a single
step approach that operates at the level of genomic DNA
prior to performing DNA amplification hence it is not
impacted by polymerase errors. The technique (Figure
1A–C) employs a thermostable duplex-specific nuclease
(DSN) (34) that digests dsDNA with high preference over
single stranded DNA and requires fully matched template
i.e. mismatches near its binding site inhibit enzymatic
action (34). DSN has no observed sequence specificity,
thereby double stranded regions are digested irrespective
of sequence. NaME-PrO harnesses these DSN properties
to enable preferential digestion of WT DNA at any desired
target. For each DNA target interrogated for mutations,
a distinct pair of oligonucleotide probes overlapping the
target region is designed. The probes are complementary
to the WT DNA and bind respectively the top and bottom
DNA template strands with an overlap ‘target’ region of
about 10–15 bp (Figure 1A–C). Excess amount of probes
are mixed with fragmented genomic DNA or circulating
DNA and denatured for 2 min at 98◦C. The temperature
is then reduced to 67◦C, while single-copy DNA sequences
remain single stranded due to low concentration and
slow re-association kinetics. The probes form preferential
binding to target DNA strands since they are designed to
have melting temperatures (Tm) of ∼65◦C when bound to
WT target DNAwhile probe-probe interactions melt below
∼50◦C, by design. Consequently, probes hybridize stably to
opposite WT DNA strands, while they generate opposing
mismatches when contacting DNA strands with mutations
in the probe overlap region, resulting in unstable hybrids.
When DSN is added in the reaction, duplexes between
probe and WT DNA strands are digested preferentially
due to DSN’s strong preference for fully-matched double
strand DNA over single stranded or mismatch-containing
DNA, thus mutant DNA strands remain substantially
intact. Since probes overlap the target sequence on oppo-
site strands, both WT DNA strands undergo preferential
digestion when a mutation is present in the probe-overlap
region. If at least one of twomutated DNA strands survives
DSN digestion, subsequent DNA amplification amplifies
exponentially these sites, thereby resulting in mutation
enrichment of all targets simultaneously. The method
creates the potential for massively parallel mutation enrich-
ment prior to sequencing and engenders a new paradigm
whereby rare mutations do not require deep sequencing for
their detection.
MATERIALS AND METHODS
Genomic DNA and circulating DNA samples
Humanmale genomic DNA (Promega Corporation,Madi-
son, WI, USA) was used as WT DNA control and was
mixed with DNA from multiple mutated cell lines or stan-
dard referenceDNAwithmultiplemutations (HorizonDis-
covery HD728) (Supplementary Table S1), to create DNA
mixtures with gradually decreasing mutation abundances.
Frozen tissue was obtained from clinical lung and colon
tumor specimens (Supplementary Table S1) provided by
theMassachusetts General Hospital Tumor Bank and used
following approval from the Internal Review Board of the
Dana Farber Cancer Institute. Genomic DNA was isolated
using the DNAeasyTM Blood & Tissue Kit (Qiagen), fol-
lowing manufacturer’s instructions.
Blood samples were obtained from colon cancer patients
and healthy volunteers (Supplementary Table S1) after in-
formed consent and Dana Farber-Cancer Institute Insti-
tutional Review Board approval. Blood samples were cen-
trifuged at 1600 g for 20 min at room temperature within
3 h from collection. Plasma was carefully removed and re-
centrifuged at 1600 g for 15min at 4◦C. Plasmawas carefully
removed and stored at −80◦C. On thawing a third and final
centrifugation was performed at 16 000 g for 5 min at room
temperature and plasma was carefully removed into a sepa-
rate tube away from any residual debris before extraction of
circulating DNA. Cell-free circulating DNA (cfDNA) was
isolated from plasma using the QIAamp Circulating Nu-
cleic Acid Kit (Qiagen), and the concentration of cfDNA
was measured on a Qubit 3.0 fluorometer (Thermo Fisher
Scientific) using a dsDNA HS assay (Q32854).
NaME-PrO oligonucleotide probe design
Probes comprised oligonucleotides 20–25 bp long such that
they have a Tm of an average 65◦C and range 63–67◦Cwhen
fully matched to WT DNA. Probes can optionally contain
a polymerase block on their 3′ end to prevent polymerase
extension in subsequent amplification reactions. Probe to
probe interactions including those from top and bottom
strand overlap were designed to have Tm < 50◦C. Inte-
grated DNA Technologies OligoAnalyzer 3.1 was used to
calculate probe Tm. A computer program was written in
Python version 2.7 for automatic probe design when tiling
of probe-overlap regions along the entire length of a DNA
sequence is desirable. The program is initialized with a ge-
nomic sequence and a start and stop index indicating the
region to be tiled. The algorithm then begins by iterating
over the sequence, constructing a set of contiguous oligonu-
cleotides which serve as the overlap regions for NaME-PrO
probes and automatically adjusting their lengths to ensure
Tm < 50◦C for each one. Once this is complete, each of
the oligonucleotides is extended toward its 5′-end to form
a pair of overlapping, isothermal probes with a Tm ∼65 ±
2◦C. The program outputs a spreadsheet containing a com-
prehensive list of sense probes, antisense probes and their
overlapping regions and respective Tm. A list of overlap-
ping probes used for singlet, multiplexed and tiling NaME-
PrO reactions are listed in Supplementary Table S2. Single
nucleotide polymorphisms (SNPs) may, in rare cases, reside
close to the targeted mutations and within the overlap re-
gion of either the upper or lower strand probes. Such SNPs
may prevent DSN from digesting WT samples effectively,
thereby leading to reduced mutation enrichment. To cir-
cumvent this hurdle, additional probes that match each of
SNP versions may be included in the assay, such that irre-
spective of what SNP is present the WT sample will always
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Figure 1. Components and workflow for nuclease-assisted minor-allele enrichment using probe-overlap (NaME-PrO). (A) Components of the assay:
partially overlapping oligonucleotide probes included in excess as compared to target DNA molar ratio; and duplex-specific nuclease (DSN). (B) The
probes are designed to bind the WT sequence of top and bottom target DNA strands. The overlap region of the probes defines the DNA region targeted
for mutation enrichment. (C) NaME-PrO workflow; following fragmented genomic DNA denaturation, the excess probes bind their targets. Addition of
DSN generated preferential digestion at double stranded regions defined by the probes, but not when there are mutation-caused mismatches. Multiple sites
can be targeted simultaneously in this manner. Subsequent amplification enhances DNA target strands that escape DSN digestion, thereby enriching for
mutated DNA.
have a fully-matched probe version. In the present work, for
simplicity, we avoided targeting somatic mutations that are
very close to mapped SNP positions.
NaME-PrO assay
Genomic DNA was treated with dsDNA Shearase Plus
(ZYMO Research, CA, USA) to generate random frag-
ments in the size range 100–500 bp. A total of 10 ng frag-
mented genomic DNA and overlapping oligonucleotides
(probes) were mixed in 1× DSN buffer to a final 10 l vol-
ume. For the lowest 0.03 and 0.01% mutation abundance
serial mutation dilution studies, 100 ng genomic DNA was
used as starting material. The final probe concentrations
ranged from 1 to 100 nM depending on whether the intent
was high enrichment with little or no quantification (50–100
nM) or modest enrichment with better quantification (1–20
nM). It is noteworthy that excessive amounts of probe di-
rected a given target can lead to elimination of mutated, as
well as WT sequences, hence increasing probe concentra-
tions beyond 50–100 nM under current assay conditions is
not recommended. The sample was placed in a SmartCycler
real-time PCR system (Cepheid) for denaturation at 98◦C
for 2 min. The temperature was then reduced to 67◦C and
0.2 units of DSN (Evrogen) was added into the mixture fol-
lowed by 20 min incubation at 67◦C and 2 min at 95◦C for
DSN inactivation. Samples where DSN was omitted (No-
DSN-controls) were run in parallel in all reactions. NaME-
PrO products were used in amplification reactions without
purification as described below.
PCR amplification
PCR reactions were performed on SmartCycler real-time
PCR system (Cepheid) or CFX ConnectTM real-time PCR
(Bio-Rad Labratories) using Phusion High-Fidelity DNA
polymerase (New England Biolabs) and LCGreen Plus+
as a fluorescence dye (BioFire Diagnositics). Primers (syn-
thesized by Integrated DNA Technologies Inc.) are listed
in Supplementary Table S3. For single-target PCR, 1 l
of DSN treated samples or No-DSN control samples were
added into a 24-l PCR master mix containing 1× Phu-
sion HF buffer, 200 nM of each primer, 200 M of each
of the four dNTPs, 0.8× LCGreen and 0.5 unit of Phusion
polymerase (Thermo Fisher Scientific). For PCR amplifica-
tion, an initial denaturation step was performed for 2min at
98◦C, followed by 45 cycles of 10 s denaturation at 98◦C, 20
s annealing at 58◦C and 10 s elongation at 72◦C. The final
step includedmelting curve analysis (0.2◦C step increments,
2 or 4 s hold before each acquisition) from 65 to 95◦C.Mul-
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tiplex PCR amplification for NaME-PrO products using
Ion AmpliseqTM Cancer Hotspot Panel v2 (207 amplicons
covering approximately 2800 COSMIC mutations from 50
oncogenes and tumor suppressor genes) was performed ac-
cording to the Ion AmpliSeq library preparation user guide
(Thermo Fisher Scientific).
Droplet digital PCR for mutation abundance validation
Droplet digital PCR (ddPCR) reactions were carried out
to verify mutation abundance before and after NaME-PrO,
as well as in the No-DSN control samples. Sequences of
primers and probes (Integrated DNA Technologies Inc.)
are listed in Supplementary Tables S3 and 4. Amplifications
were performed in a 20 l volume containing 1× ddPCR
Supermix for probes (Bio-Rad), 900 nM forward and re-
verse primers, 250 nM 6-carboxyfluorescein (FAM) and
6 - carboxy - 2’,4,4’,5’,7,7’ - hexachlorofluorescein (HEX)
probes (Integrated DNA Technologies) and 10 ng genomic
DNA or real-time PCR products (using 1–1 000 000 final
dilution for PCR products). Droplets were then generated
using the DG8TM droplet generator cartridges (Bio-Rad)
which contained 20 l aqueous phase with 70 l of droplet
generation (DG) oil (Bio-Rad). Samples were transferred
to a 96-well reaction plate and then sealed using the PX1
PCR plate sealer (Bio-Rad) for 10 s at 180◦C prior to ther-
mal cycling. The thermal cycling program was performed
on an Eppendorf Mastercycler ep Gradient S (Eppendorf)
with an initial denaturation step at 95◦C for 10 min, fol-
lowed by 40 cycles of 30 s denaturation at 94◦C, 60 s an-
nealing at 58◦C and with a final step holding at 98◦C for
10 min. Then the plate was transferred to QX100 droplet
reader (Bio-Rad) for endpoint reading. Calculation of ab-
solute number of positive events for a given channel (FAM
or HEX), the ratio and the fractional abundance of mu-
tation for each sample were performed by the Quantasoft
Software (Bio-Rad). The determination of number of tar-
get copies per droplet (number of copies of target molecule)
was adjusted by the software to fit a Poisson distribution
model with 95% confidence level.
Fifty-plex PCR preamplification for examining the NaME-
PrO enrichment limits
Fifty-plex PCR primers (Supplementary Table S5) were
designed for commonly mutated exonic regions identified
in lung and esophageal cancers according to the COS-
MIC database, as previously reported (17). Multiplex pre-
amplification from 20 ng genomic DNA was performed in
a total volume of 25 microlitters using a mixture of 100
primers (50 paired sets) at a final concentration of 0.3 mM
for each primer with 0.3 mM dNTPs, 3 mM MgCl2, 1×
Kapa HiFi buffer and 0.5U of Kapa HiFi HotStart DNA
polymerase (Kapa Biosystems) reported to have an aver-
age error rate of 2.8 × 10−7 mis-incorporations/bp. Mul-
tiplex PCR cycling was performed according to the manu-
facturer’s recommendations (Kapa Biosystems) for a total
of 20 PCR cycles using 63◦C as optimal annealing temper-
ature. Amplicon lengths ranged from 120 to 190 bp in size
depending on the amplicon (Supplementary Table S5). Fol-
lowing multiplex cycling, 1 ml of exonuclease I (New Eng-
land Biolabs) was added to each reaction and incubated at
37◦C for 30 min and 80◦C for 15 min to remove unincorpo-
rated primers.
COLD-PCR
COLD-PCR for KRAS exon 2 DNA fragments was con-
ducted either directly from genomic DNA or following
NaME-PrO treatment of genomic DNA from lung tumor
sample TL119, as previously described (35,36). COLD-
PCR products were analyzed via Sanger sequencing.
SNP genotyping assay
TaqMan R© SNP genotyping assays were purchased from
Thermo Fisher Scientific for a number of SNP loci, in-
cluding rs1050171. Genotyping reactions for cfDNA sam-
ples were conducted following manufacturer instructions
on CFX ConnectTM real-time PCR. Thermo cycling com-
prised initial denaturation for 10 min at 95◦C, followed by
40 cycles of 15 s denaturation at 95◦C, 1 min annealing
and extension at 60◦C. Cell-free circulating DNA (cfDNA)
from healthy volunteer blood samples were tested via SNP
genotyping assays to identify samples that differ at the
tested SNP positions. Samples with different genotypes of
rs1050171 were mixed to obtain a gradually increasing 1
to 5% SNP-abundance. The probe and primer sets used
in TaqMan R© SNP genotyping assays were also used in
ddPCR format to quantify the genotype abundances of
cfDNA mixtures formed by mixing cfDNA samples carry-
ing different genotypes. SNP abundance was quantified via
ddPCR before and after NaME-PrO reactions.
NaME-PrO applied to error-prone PCR (EP-PCR) products
Multiplexed-PCR amplicons containing randommutations
were created using error-prone PCR (EP-PCR) following a
published protocol (37). Briefly, PCR reactions were per-
formed on SmartCycler real-time PCR system (Cepheid). A
total of 100 ng of Human genomic DNA (Promega Corpo-
ration) were added into 99 l EP-PCRmaster mix contain-
ing 10 mMTris·HCl (pH 8.3), 7 mMMgCl2, 1 mMdCTP, 1
mM dTTP, 0.2 mM dATP, 0.2 mM dGTP, 55-plex reaction
primers (final 0.3 M each, sequences listed in Supplemen-
tary Table S5), 0.5 mM MnCl2 and 5 unit of GoTaq Flexi
DNA polymerase (Promega Corporation). To achieve EP-
PCR products with different mutation abundances, 10, 20
and 30 PCR cycles (94◦C for 1 min, 60◦C for 1 min, 72◦C
for 3 min) were performed respectively. The products were
treated with 30 units of Exonuclease I (New England Bi-
olabs Inc) to remove the excess primers. Mutations in EP-
PCR products were tested via high resolution melting anal-
ysis (HRM) before and after application of NaME-PrO.
High resolution melting (HRM) analysis
Ten-microliter of PCRproduct were transferred to a 96-well
plate, and 20l of mineral oil was added to each well. HRM
was performed on a 96-well LightScanner R© system (Idaho
Technology). The software sensitivity level was set as 1.2
for computing DNA variant groups. All experiments were
replicated at least three independent times for assessing the
reproducibility of the results.
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Sanger sequencing
The PCR products were digested by Exonuclease I and
Shrimp Alkaline Phosphatase (New England Biolabs) and
processed for Sanger sequencing at Eton Bioscience Inc. To
enable sequencing of short PCR amplicons, a 30-T tail was
added to the 5′-end of the forward primer.
Illumina MiSeq sequencing of PCR products after NaME-
PrO assay
Following NaME-PrO-PCR, mutation enriched products
were processed using the standard barcoding and library
preparation protocol for Illumina MiSeq sequencing. Li-
brary preparation was performed at the Center for Cancer
Computational Biology at the Dana-Farber Cancer Insti-
tute. Libraries with ligated Illumina adapters were assessed
for DNA quality and quantity on Agilent bio-analyzer, and
then pooled together into a single tube prior to MiSeq se-
quencing. Data analysis was conducted onMiSeq Reporter
software and the alignment sequencing data were loaded
into Integrative Genome Viewer 2.3 (IGV, Broad Institute)
using human genome hg19 as reference. Reads for each non-
reference bases at the nucleotide of interest as well as the ad-
jacent nucleotides were recorded and plotted in a noise plot
to distinguish the true mutation versus background noise.
RESULTS
Single target NaME-PrO: proof of principle
We first applied NaME-PrO to genomic DNA with KRAS
exon 2 (p.G12V, c.34G > T) mutations. WT DNA was
mixed with SW480 cell line DNA, resulting in DNA with
∼0.5% abundant KRASmutation. Following random frag-
mentation of genomicDNA,NaME-PrOwas applied along
with control experiments. Samples were PCR amplified
and ddPCR was employed to quantify the KRAS muta-
tion abundance before and after NaME-PrO. The probe se-
quences for NaME-PrO, primers and hydrolysis probes for
PCR and ddPCR are listed in Supplementary Tables S3 and
S4. When DSN and both overlapping probes are present, a
167-fold enrichment mutation enrichment is achieved (Fig-
ure 2) converting an original 0.5% mutation abundance to
83.7% abundance. In the presence of only one probe, or
when a probe overlapping the mutation is combined with
an opposite strand probe that does not overlap, the muta-
tion enrichment is lower than when both probes overlap the
mutation location. When NaME-PrO is applied on DNA
with KRAS mutations using probes specific to a different
location (TP53 exon 8) the KRAS mutation abundance is
not affected, indicating the specificity of the process for the
sequence targeted by the overlapping probes.
Multiplexed NaME-PrO
To apply NaME-PrO in a multiplexed fashion, we first de-
signed a duplex assay for KRAS exon 2 and TP53 exon
8 mutations. Supplementary Figure S1 shows that both
KRAS and TP53 mutations are enriched, for two distinct
sets of mutations encompassed under a single set of probes
for each gene. Next we used genomic DNA containing mul-
tiple clinically relevant mutations at ∼1% abundance (HDx
Figure 2. NaME-PrO applied to a single target. Genomic DNA with
∼0.5% mutation in KRAS exon 2 plus a mutation in TP53 exon 8 was
tested for mutation abundance before and after KRAS-directed NaME-
PrO using droplet digital PCR (ddPCR). Presence of two KRAS-specific
overlapping probes plus DSN nuclease generate the highest KRAS mu-
tation enrichment (∼167-fold, resulting to a clonal mutation). Omission
of any system component, or using only one probe, two non-overlapping
probes (‘probe plus cutter’) or probes directed to the wrong target (TP53)
result to lower mutation enrichment or no enrichment at all. Experiments
were repeated five independent times.
DNA), in order to examine a 9-plex NaME-PrO assay,
using 50Mm concentration for all probes. All mutations
targeted by NaME-PrO probes are significantly enriched
to clonal mutation status (>50% abundance, Figure 3A).
When downstream analysis is performed using (38) HRM
or Sanger sequencing, detection sensitivity is enhanced via
NaME-PrO for both these detection methods (Supplemen-
tary Figure S2). To understand the dependence of mutation
enrichment on probe concentration we performed ddPCR
evaluations versus probe concentration and initial muta-
tion abundance. Probes for two targets, IDH1 and BRAF
were followed within a 9-plexed reaction. For probe con-
centration of 50 nM or higher, mutation enrichment is high
but not quantitatively related to original mutation abun-
dance Supplementary Figure S3. In contrast, probe concen-
trations in the region 3–10 nM for the two targets provide
modest enrichment bearing proportionality to the original
mutation abundance. Accordingly, individual probe con-
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Figure 3. MultiplexedNaME-PrO directed to 9–50 clinically relevant DNA targets. (A) 9-plex-NaME-PrO applied to genomicDNA containingmutations
at ∼1% abundance at nine clinically relevant sites. Mutation enrichment to 80–95%mutation abundance is observed for all targets via droplet-digital-PCR
(ddPCR). (B) 50-plex-NaME-PrO applied to genomic DNA containing mutations at ∼1% abundance at the same nine clinically relevant sites as in (A).
Mutation enrichment to 80–95% mutation abundance is observed for all targets. (C) Serial dilution study to examine NaME-PrO mutation enrichment at
low mutation abundances. Genomic DNA contained serial mutant dilutions with mutation abundance of ∼1, 0.3, 0.1, 0.03 and 0.01% in all nine DNA
targets tested. For the lowest three dilutions the amount of starting DNA was increased to 100 ng to ensure adequate number of mutated sequences in the
sample. (D) Plots of mutation abundance after NaME-PrO against mutation abundance in starting genomic DNA as quantified via ddPCR. Experiments
were repeated three independent times.
centrations withinmultiplexedNaME-PrO reactions can be
modulated to yield the desired endpoint. We then designed
probes for another 41 target sequences to generate a 50-
plex probe pool for simultaneous enrichment to these tar-
gets. Figure 3B depicts mutation abundance for the nine tar-
gets examined. The 50-plex NaME-PrO resulted to similar
levels of enrichment as the 9-plex reaction, converting mu-
tations from 1% initial mutation abundance to clonal sta-
tus. These data reveal the specificity of the process and the
absence of significant illegitimate interactions with probes
targeting different DNA targets (Figure 3B). Following 50-
plexNaME-PrO onHDxDNA containing 1% original mu-
tation abundance, we also utilized a commercially avail-
able panel, Ion Ampliseq Cancer Hotspot Panel v2, to con-
duct 207-plex PCR. This resulted to 50–100-fold mutation
enrichment in the targets followed (Supplementary Figure
S4). In summary, we demonstrated that NaME-PrO en-
ables multi-target mutation enrichment by∼50-fold to over
∼200-fold depending on conditions and can be combined
with targeted cancer panel applications.
NaME-PrO applied to serial mutation dilutions
To evaluate further the enrichment potential of NaME-
PrO, we applied the technology tomutatedDNAdiluted se-
rially into WT DNA. Fragmented genomic DNA contain-
ingmultiplemutations at∼5, 1, 0.3, 0.1, 0.03 and 0.01%mu-
tation abundances was obtained by serial dilution of HDx
DNA intoWTDNA, then screened viamultiplexedNaME-
PrO and assessed via ddPCR (Figure 3C). The data indicate
that the targeted mutations are enriched and distinguished
from WT DNA down to ∼0.01% abundance. The original
mutation abundance is logarithmically correlated (R2 > 0.9)
to the NaME-PrO-derivedmutation abundance with differ-
ences depending on mutation type and position, as well as
on the individual probe concentrations used for the targeted
site (Figure 3D and Supplementary Table S6).
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To determine the technical limits of NaME-PrO muta-
tion enrichment we also conducted an extended dilution se-
ries, down to one mutant molecule in 3 × 106 WT alleles
for IDH1 mutations. Since it is difficult to perform PCR di-
rectly on genomicDNAcontaining 3× 106 human genomes
(18 g), we performed a few cycles of high fidelity 50-plex
PCR pre-amplification separately for DNA with 5% muta-
tion abundance and for WT DNA. The pre-amplified mu-
tated PCR products were then serially diluted in WT pre-
amplification products to form the desired final mutant ra-
tios. Special precautions to exclude airborne contamina-
tion were adopted. To account for potential interference
by polymerase-introduced errors we amplifiedWTDNA in
parallel, in five independent experiments. NaME-PrO was
then applied to these samples under conditions for maxi-
mum enrichment, followed by HRM and Sanger sequenc-
ing to detect IDH1 mutations (c. 394C > T, p.R132C, Sup-
plementary Figure S5). Both HRM and Sanger sequencing
were able to identify IDH1 mutations down to 0.00003%,
(∼1 mutant allele in 3 million WT alleles), while WT-only
samples did not indicate mutations. In summary, under
highest-enrichment conditions NaME-PrO can result to al-
most complete isolation of mutated samples from large ex-
cess WT DNA.
NaME-PrO applied to tumor samples and plasma-
circulating DNA
To generate cfDNA with mutations at specific sites we ex-
tracted cfDNA from blood of healthy individuals and then
‘spiked’ fragmented genomic DNA containing mutations,
to generate 1%mutation abundances at 10 known positions.
Then a 10-plex NaME-PrO assay was applied to enrich mu-
tations, followed by PCR amplification and ddPCR detec-
tion. Similar levels of mutation enrichment using cfDNA,
as with fragmented genomic DNA were observed (Figure
4A).
Next we examined cfDNA extracted from plasma of
Stage III colon cancer patients. We conducted 10-plex
NaME-PrO for cfDNA from nine patients and two healthy
volunteers, and applied ddPCR to identify KRAS hotspot
mutations both with and without application of NaME-
PrO (Figure 4B). Using ddPCR alone, we found that
two patients had very low levels KRAS G12V muta-
tions while the remaining samples and negative controls
yielded ddPCR signals below the ddPCR detection limit
(∼0.05%). Accounting for background ‘limit-of-blank’ sig-
nals, ddPCRderivedmutations have an abundance of about
0.05%. Samples treated with NaME-PrO identified the
same positive and negative cfDNA samples with ddPCR
and enriched mutations in the twomutant samples to about
4 and 6%, respectively (Figure 4B). T he NaME-PrO-
projected original mutation abundances using Supplemen-
tary Table S6 are 0.05 and 0.07%, respectively, in agreement
with ddPCR quantification. The mutations become clearly
more evident using NaME-PrO-ddPCR instead of ddPCR
alone.
Next, NaME-PrO was applied to genomic DNA from
colon and lung tumor samples previously shown to harbor
clonal or low-level mutations in KRAS and TP53 (28). One
of these samples TL119 harbors low abundance GG > TT
KRAS mutations (39) which was not detectable on Sanger
sequencing but was enriched and became clearly visible fol-
lowing NaME-PrO-PCR-sequencing (Supplementary Fig-
ure S6). When PCR was replaced by COLD-PCR, which
provides additional mutation enrichment (36,40,41), the re-
sulting mutation abundance in TL119 was ∼90% indicat-
ing synergism between NaME-PrO and COLD-PCR. Two
additional samples, CT20 and TL121 previously shown to
harbor two low-level mutations in distinct exons of TP53
(39) were screened following NaME-PrO containing probes
targeting TP53 exons 7–9, Figure 4C. Enrichment was ob-
tained on both mutation sites for each sample.
Circulating DNA may serve as an early biomarker for
solid organ transplant rejection (4). An increase of donor
circulating DNA as a fraction of total recipient cfDNA in
the narrow range from 1 to 5% is an indicator of impend-
ing acute rejection (4). To simulate a transplant rejection
situation we identified SNPs that differ in cfDNA from two
healthy donors, using ddPCR; we then mixed stochiomet-
rically the two cfDNA samples such that SNPs appear in
fractions of 1–5% of the total representing. These samples
were then examined either directly via ddPCR, or by ap-
plying NaME-PrO-ddPCR to derive the fraction of donor
DNA.NaME-PrO conditions were adjusted in favor or pre-
serving quantification rather than maximizing enrichment.
Figure 4D indicates that, followingNaME-PrO, the quanti-
tative difference corresponding to stable disease vs. acute re-
jection is broadened, thus potentially facilitating detection
of clinically significant cfDNA increase in transplantation
patients.
NaME-PrO application with targeted re-sequencing
Combination of NaME-PrO with MPS is suitable since
both technologies address multiple targets simultaneously.
50-plex NaME-PrO was applied to fragmented genomic
DNA or plasma-circulating DNA containing mutations at
0.5% prevalence, followed by targeted PCR amplification
and library preparation for MiSeq sequencing, following
our previously described protocol (28). Amplicon regions
produced by targeted PCR amplification were paired-end
sequenced on the Illumina Miseq and aligned to the refer-
ence genome (GRh37/hg19). Frequency calls were gener-
ated for each nucleotide aligned within the amplicon loca-
tions in order to develop ‘variant-and-noise plots’ to display
both the frequencies of mutation calls and the background
signals. Figure 5 and Supplementary Figure S7 show repre-
sentative variant-and-noise plots for genomicDNAand cir-
culating DNA containing KRAS, BRAF, MEK1 and IDH1
mutations with or without NaME-PrO in the workflow.
Consistent with previous observations (28), in the absence
of NaME-PrO, targeted re-sequencing cannot distinguish
0.5% mutations from noise levels. Following NaME-PrO,
the mutation abundance increases to levels that are clearly
distinguished from noise.
NaME-PrO assay ‘tiling’ for enrichment at multiple muta-
tion positions
To examine the ability of NaME-PrO to enrich mutations
at multiple positions on target sequences, as opposed to tar-
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Figure 4. Multiplexed NaME-PrO applied to plasma-circulating DNA (cfDNA) and genomic DNA from colon/lung tumors obtained under consent
and IRB approval. (A) Multiplexed-NaME-PrO applied to cfDNA from normal volunteers spiked with fragmented genomic DNA to generate ∼1%
mutation abundance at 10 clinically relevant sites. ddPCR was used to evaluate mutation abundance. Mutation enrichment is evident at all sites tested.
(B) Multiplexed NaME-PrO applied to cfDNA obtained from nine colon cancer patients, two healthy volunteers and standard reference DNA, HMC.
Two cfDNA samples were deemed asKRASG12Vmutation-positive via ddPCRwhile the rest exhibited signals below the ddPCR detection threshold and
deemed to be negative. NaME-PrO-treated samples enriched highly the twoKRAS positive samples but not the negative samples, thus boosting the signal to
noise ratio. (C) MultiplexedNaME-PrO applied to clinical tumor genomic DNA samples previously shown to harbor low-level mutations at multiple TP53
exons. Sanger sequencing following NaME-PrO enables detection of the enriched low-level mutations. (D) Multiplexed NaME-PrO followed by ddPCR,
applied to a cfDNA from two normal volunteers differing at SNP rs1050171. cfDNA was mixed to generate SNP proportions increasing gradually from
1 to 5%, to simulate differences observed in stable versus acute solid organ transplantation rejection(4). NaME-PrO conditions were adjusted in favor of
preserving quantification rather than maximizing enrichment, using 10 nM probe concentration. Application of NaME-PrO enriches DNA alterations
and enlarges the clinically significant differences between 1 and 5% ‘donor’ cfDNA. Experiments were repeated three to five independent times.
geting ‘hotspot’ mutations, we applied a single set of over-
lapping probes for enriching three distinctKRASmutations
falling within the probe overlap region.Mutations at all po-
sitionswere enriched (Supplementary Figure S8), indicating
that mismatches of diverse types and positions within the
probe overlap region inhibit DSN digestion effectively.
In order to further examine the ability of NaME-PrO to
enrich diverse mutations, we also generated random muta-
genesis DNA templates by EP-PCR, followed by HRM of
the resulting amplicons. The mis-incorporation-error abun-
dance of an EP-PCR amplicon depends on the number of
PCR duplications (42). As shown in Supplementary Figure
S9, in the absence of NaME-PrO, amplicons required 30
cycles of EP-PCR to become distinguished fromWT DNA
via HRM, for both KRAS and IDH1. When NaME-PrO
was applied, 10-cycle EP-PCR products were clearly distin-
guished from WT, consistent with NaME-PrO enrichment
of EP-PCR generated randommutations and enhancement
of HRM sensitivity for detecting polymerase-induced base
changes.
Finally, we adapted NaME-PrO to encompass mutation
enrichment along all sequence positions in TP53 exons 6 to
exon 9 by ‘tiling’ probe overlap regions along exons of inter-
est and performing multiple NaME-PrO assays in parallel.
The strategy is depicted in Supplementary Figure S10. Each
exon is divided into 7–10 successive target regions and over-
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Figure 5. MultiplexedNaME-PrO combinedwith targeted re-sequencing.Multiplexed-NaME-PrO applied to cfDNA from normal volunteers spikedwith
fragmented genomicDNA to generate∼0.5%mutation abundance at multiple clinically relevant sites. FollowingNaME-PrO, samples were PCR-amplified
and processed for library preparation. Variant to noise plots derived from Illumina MiSeq sequencing data are depicted. (A and B) KRAS G12V, G12R,
G13Dmutations in fragmented genomic DNAwith and without application of NaME-PrO, respectively. (C andD) IDH1R132Cmutation in cfDNAwith
and without NaME-PrO, respectively. The original mutation abundance is 0.5% in both cases, while the read depth is about 1000–2000× depending on
sequence. Inserts in B and D represent magnified versions of the same graphs to depict clearly the effect of sequencing noise. Application of NaME-PrO
increases the signal-to-noise ratio and reveals clearly the rare mutation. Experiments were repeated two independent times.
lapping probes corresponding to contiguous 10–15 bp re-
gions are designed to ‘tile’ the entire interrogatedDNA frag-
ment. Probes are then mixed to form 7–10 groups such that
every group contains a single pair of overlapping probes for
each interrogated DNA fragment. The interrogated DNA
samples are then split in 7–10 parallel reactions andNaME-
PrO is applied separately to them, enriching mutations on
a single portion from every exon simultaneously. By pool-
ing results from all NaME-PrO reactions, mutations from
all positions on the sequences are enriched. Since genomic
DNA is fragmented to an average size of∼150 bp, a limited
number of tiled NaME-PrO reactions ensure all sequences
on an average size fragment are addressed by a pair of over-
lapping probes. To include longer exons or higher num-
bers of exons, only the number of probes within each group
needs to increase, while the number of distinct NaME-PrO
reactions need not change. Supplementary Figure S10A de-
picts simultaneous enrichment of mutations alongTP53 ex-
ons 6–9 in a human DNA sample containing single muta-
tions in all four exons. Supplementary Figure S10B depicts
enrichment ofmultiple randommutations generated by EP-
PCR along TP53 exon 8. By tiling NaME-PrO probes in
seven groups, HRM-based identification of 0.1–1% muta-
tion abundance in all TP53 exon 8 segments is demon-
strated.
DISCUSSION
We introduced and experimentally validated NaME-PrO, a
highly parallel approach for eliminating excess WT DNA
that does not provide incremental biological or clinical
value, in order to boost analysis of clinically significant
rare DNA variants. Previous enzymatic approaches for re-
moving WT DNA (19–23) relied on enzymes that digest
only at specific sequences, limiting their broad application.
The non-selective, DNAse-like activity of DSN in combi-
nation with ∼10–15 bp target regions defined by overlap-
ping probes engender NaME-PrO with the potential for
massively parallel degradation of WT DNA. Indeed, the
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main condition required is the hybridization of appropri-
ately designed probes to the chosen targets in the start-
ing DNA material (Figure 1C). This step is already estab-
lished in existing sample preparation workflows for thou-
sands of targets including the whole exome (43). The poten-
tial implication for MPS is that a limited read depth may
be adequate to identify low-level events reliably, and that
deep sequencing may not be necessary, leading to substan-
tial speed and cost benefits. For example, using NaME-PrO
0.5% abundance mutations are enhanced by orders of mag-
nitude, such that they would be detected with just 10–30
reads (Figure 5 and Supplementary Figure S7). By adjust-
ing probe concentration and potentially including modified
bases in probe design it may eventually be possible to enable
near complete separation of large genomic fractions out of
mixed clinical samples, as shown in Supplementary Figure
S5 for IDH1, thereby resulting to highly simplified and cost-
effective sequencing. To preserve quantification of origi-
nal mutation abundances on the other hand, lower probe
concentrations combined with modest, quantitative enrich-
ment can be adopted.
Since NaME-PrO is applied at the genomic DNA level,
prior to other treatments, it combines with downstream
sample preparation, amplification or endpoint detection
methods, with almost no change in the existing work-
flows. For example, boosting the sensitivity of sequencing,
HRM, ddPCR, COLD-PCR (Figures 2–5) did not require
a change in the established processes. Of note, the end-
point mutation readout method still determines the final
outcome, e.g. a 0.1%mutation enriched viaNaME-PrO to a
level of 7–10% mutation abundance may still be missed via
Sanger sequencing, while it would be detectable via next-
generation sequencing.While techniques like real time PCR
(44,45), ddPCR (46) or BEAM-ing (47) also allow high
mutation detection sensitivity, these are limited to exam-
ining a single target per reaction, as opposed to NaME-
PrO that can address a broad target footprint. In summary,
NaME-PrO provides a simple and powerful process to re-
move WT-DNA in large numbers of sequences that raises
long-standing limitations in identification and tracking of
rare, clinically useful DNA sequences.
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